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Abstract
Lipoprotein(a) [Lp(a)] is a LDL-like particle containing a single copy of apolipoprotein B-100 (apoB-100), covalently attached to apo-
lipoprotein(a) [apo(a)]. Apo(a) is encoded by LPA gene (6q26-27), and it has been hypothesized that LPA +93C>T and +121G>A poly-
morphisms in the 5 Xanking region could inXuence the apolipoprotein(a) synthesis, so aVecting Lp(a) levels. In order to permit a rapid
detection of LPA polymorphisms, we performed an analysis protocol for the SNPs detection through Nanogen Technology with the Uni-
versal Reporting System, and we compared our results with those obtained with a more conventional method, such as PCR-RFLP assay.
Our experiments evidenced that Nanogen Technology may be used as a high-throughput tool in LPA +93C>T and +121G>A polymor-
phisms analysis, minimizing the hands-on time and the costs for the SNPs detection. In particular, this Technology allows the analysis of
polymorphisms at the LPA locus, able to modulate the levels of Lp(a), a relevant marker of atherosclerosis.
© 2007 Elsevier Inc. All rights reserved.
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Lipoprotein(a) [Lp(a)] is a LDL-like particle contain-
ing a cholesteryl ester-rich core, a single copy of apolipo-
protein B-100 (apoB-100), covalently attached to the
distinctive molecule of apolipoprotein(a) [apo(a)]. Data
from a large number of clinical studies evidenced an asso-
ciation between high Lp(a) levels and an increased risk for
atherosclerotic disease including coronary artery disease
and stroke [1–3].
Apo(a) is a high molecular weight glycoprotein of 300–
700 kD [4], sharing homologous domains with plasmino-
gen, kringle 4 (K4) and kringle 5 (K5) [5], and it is subjected
to size heterogeneity because of the presence of a variable
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doi:10.1016/j.ymgme.2006.12.011number of the K4 repeat unit (from 3 to more than 40 cop-
ies) [6].
Plasma Lp(a) concentration is characterized by a wide
inter-individual variability (ranging from <0.1 to
>200 mg/dl) [7,8], while it remains relatively constant
throughout life [9,10]. It has been evidenced an inverse
relationship between Lp(a) levels and the apo(a) size [11–
13]: smaller apo(a) sizes seem to be related to higher Lp(a)
plasma levels [6].
Apo(a) is encoded by LPA gene (6q26-27) [14] (NCBI
OYcial Gene Name: lipoprotein, Lp(a); Accession No.
NT_007422), hypothesized to be responsible for more than
90% of variability in Lp(a) levels and the varying number of
K4 repeats seems to account for about 70% of these varia-
tions [15,16].
Nevertheless, it has been observed a signiWcant variabil-
ity in the Lp(a) levels among individuals having the same
apo(a) size-isoform [12,17], so suggesting that polymorphisms
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Several single nucleotide polymorphisms (SNPs) have been
identiWed in the LPA gene 5-Xanking region and in vitro
studies, by chloramphenicol acetyltransferase (CAT) assay,
evidenced a role for LPA +93 C>T and +121 G>A SNPs in
modulating the promoter activity [5]. It has been hypothe-
sized that both sites may have signiWcant eVects on LPA
gene expression, as conWrmed by site-directed mutagenesis
[5,18]. However, the +93C>T variation has been observed
to reduce the eYciency in translation, rather than transcrip-
tion. It has been shown that the C>T transition introduces
an additional upstream ATG translation start codon, thus
leading to a 60% reduction in protein translation [19]. Con-
cerning the LPA +121G>A SNP, it has been hypothesized
a positive regulation on gene expression, so contributing to
the modulation of Lp(a) plasma levels [5,20].
In this study, we have considered DNA microarray
technology in order to analyze LPA +93C>T and
+121G>A polymorphisms. Medium to high-throughput
techniques, that permit to carry out rapid, accurate and a
highly reliable genotyping, are now available. In particu-
lar, a recently developed technology, based on the appli-
cation of an electric Weld and allowing the rapid
deposition of biotinylated PCR products on a streptavi-
din-coated array, is composed of 10 £ 10 addressable test
sites (Nanogen Technology) [21,22]. The addressed ampli-
cons are then hybridized to Xuorescent-labeled speciWc
oligonucleotide reporters, so permitting the discrimina-
tion among homozygotes for the wild-type and the rare
allele and heterozygous samples at a speciWc incubation
temperature.
Here we have taken into account the NanoChip Technol-
ogy in the detection of LPA +93C>T and +121G>A
polymorphisms, thus comparing the accuracy of this
high-throughput system to traditional assays (PCR-RFLP
analysis). Nanogen Technology allows a rapid detection of
LPA 5 upstream polymorphisms and may be useful in the
evaluation of the genotype–phenotype relationship on a large
number of samples, in order to better deWne the role of these
polymorphisms in the modulation of Lp(a) levels, in consid-
eration of the relevant role of Lp(a) in atherosclerosis.Methods
Study population
Blood samples are obtained from 647 clinically healthy subjects, living
in Florence (Italy) and recruited from the population study “Progetto
Nutrizione per la Salute e la prevenzione di Malattia” [23].
LPA +93C>T and +121G>A gene polymorphisms detection
Genomic DNA has been extracted from peripheral blood leukocytes
by using the Flexigene DNA kit (Qiagen, GmbH, Germany).
PCR ampliWcation and Nanochip platform analysis
LPA +93C>T and +121G>A polymorphisms have been evaluated
through Nanogen Technology (NanoChip® Molecular Biology Worksta-
Fig. 1. (a) Electronic microchip characterized by the presence of 10 £ 10
addressable sites (Nanogen Cartridge). (b) The Universal Reporting Sys-
tem is based on the use of a stabilizer and of mutant and wild-type report-
ers, consisting of a binding sequence, complementary to the gene, and of a
tail sequence, unrelated to the gene sequence itself.Table 1
LPA +93C>T and +121G>A Nanogen oligonucleotide sequences
a Melting temperature.
b Discrimination temperature.
SNP Oligonucleotide Sequence Tm
a (°C) Td
b (°C)
LPA +93C>T Wild-type reporter 5-ctgagtccgaacattgagccGTAAGTCAACAAC-3 34.0 37.0
Mutant reporter 5-gcagtatatcgcttgacattTGTAAGTCAACAAT-3 35.4
Stabilizer 5-GTCCTGGGATTGGGA-3 50.3
LPA +121G>A Wild-type reporter 5-ctgagtccgaacattgagttACACTTTCTGGG-3 37.5 37.0
Mutant reporter 5-gcagtatatcgcttgacattACACTTTCTGGA-3 35.2
Stabilizer 5-CACTGCTGGCCAGTCCCAAAATGGAACATAAGGA-3 65.6
TAIL-1 5-ctgagtccgaacattgag-3
TAIL-2 5-gcagtatatcgcttgaca-3
Universal reporter 1 5-ctcaatgttcggactcag-3
Universal reporter 2 5-tgtcaagcgatatactgc-3
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accordingly to protocols extensively described in a previous paper [21].
Moreover, we used the Universal Reporting System in order to limit the
necessity to purchase expensive labeled-reporters [24]. The ampliWcation of
the sequence containing the two SNPs has been performed through PCR
reaction in a MJ thermocycler (MJ Research, Waltham, MA, USA) with
the following settings: one denaturation cycle at 95 °C for 5, 35 cycles
with denaturation at 94 °C for 1, annealing at 54 °C for 50 and extension
at 72 °C for 50, followed by a Wnal extension at 72 °C for 7’. The reaction
has been performed in a Wnal volume of 25 l with 100 ng of genomic
DNA, 0.2 mM of each dNTP, 1 l of a 10 M forward primer (5-TGACA
TTGCACTCTCAAATATTTT-3), 1l of a 10M reverse primer (5-biotin-
AGAACCACTTCCTTATGTTCCA-3) and 0.5 U of Taq polymerase
(GoTaq, Promega Italia, Milano, Italy) in 1£ PCR BuVer.
The amplicons have been desalted with Nucleo Fast System (96-well
PCR plates) from Macherey–Nagel (Macherey–Nagel Gmbh & Co. KG,
Düren, Germany).
A 30 l volume from puriWed samples has been mixed with 30 l of
100 mM histidine and placed in a 96-well Nunc plate (Nalge Nunc interna-
tional, Rochester, NY, USA). A 0.3 M NaOH solution, requested for the
denaturation of the PCR product, a 50 mM histidine solution and three
heterozygous control samples, have also been added to the plate. The sam-
ples prepared as described previously, according to NanoChip guidelines,
have been electronically addressed to the test sites (pads) on the cartridge.
Histidine 50 mM without amplicons has been bound to two pads of the
chip for background subtraction.
After the addressing of the amplicons on the array, the chip has been
rinsed with 150 l of High Salt BuVer (50 mM sodium phosphate and
500 mM sodium chloride, pH 7.4) for 3 and next with 100 l of hybridiza-
tion mix, before loading the cartridge into the instrument for the Xuores-
cence scanning at the speciWc discrimination temperature (Table 1).
The hybridization mix contains 200 pmol of stabilizer, 100 pmol of
wild-type and mutant reporter probe and 100 pmol of both Cy3 and Cy5-labeled universal reporter [24] (Table 1). Fluorescent oligonucleotide
probes, speciWc for the wild-type and for the mutant allele recognize the
sequence containing the SNP site and its 3-Xanking region. Each reporter
probe has a tail at the 5-terminus that is not complementary to the gene
sequence but it hybridizes in a speciWc way with the universal reporters
(Fig. 1).
The probe complementary to the tail of the wild-type reporter is 3-
labeled with Cyanine 3 (Cy3), while the probe complementary to the tail of
the mutant reporter is 3-labeled with Cyanine 5 (Cy5). The diVerence in
hybridization energy between the matched and mismatched reporters was
enhanced by a stabilizer oligonucleotide, which hybridizes in a strict prox-
imity of the reporter detection probe with the gene sequence surrounding
the SNP site; thus providing a base-stacking energy in order to improve
the allele discrimination.
The mutation analysis is performed with a software that calculates
the Xuorescence values from each sample. Recorded values from hetero-
zygous control samples are used to normalize the Cy3/Cy5 signals to a
value of 1. The mean values for Cy3 (green bar graph) and Cy5 (red bar
graph) Xuorescence are obtained by averaging the amount of Xuores-
cence in each pad and the software assigns directly the genotype to each
sample by considering the Cy5/Cy3 ratio both for LPA +93C>T and
+121G>A gene polymorphisms (Fig. 2). Samples demonstrating a
Cy3:Cy5 signal ratio >5:1 or >1:5 have been assigned as wild-type
homozygotes or mutant homozygotes, respectively; while samples with a
Cy3:Cy5 signal ratio between 1:3 or 3:1 have been assigned as heterozyg-
otes, as a default. Test sites with a signal-to-noise ratio (SNR) <5 and
Cy5:Cy3 Xuorescence values between 1:3 and 1:5 or 3:1 and 5:1 have
been excluded from the analysis.
PCR-RFLP assay
LPA +93C>T and +121G>A polymorphisms have also been detected
with PCR-RFLP analysis. The sequence surrounding the two SNPs has
been ampliWed through PCR reaction at an annealing temperature ofFig. 2. The mean values for Cy3 (green bar graph) and Cy5 (red bar graph) Xuorescence are obtained by averaging the amount of Xuorescence in each pad
and the software assigns directly the genotype to each sample by considering the Cy5/Cy3 ratio. If Cy5/Cy3 Xuorescence ratio lies between 3:1 and 1:3,
samples are designated as heterozygous, if Cy5/Cy3 ratio is >5:1, they are considered wild-type homozygous and if Cy5/Cy3 ratio is <1:5 mutant homozy-
gous. (a) LPA +93C>T genotyping results (Xuorescence histograms and array image). (b) LPA +121G>A genotyping results (Xuorescence histograms and
array image). (For interpretation of the references to color in this Wgure legend, the reader is referred to the web version of this article.)
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tion) and the same experimental procedure taken into account in the
Nanochip analysis. In order to detect LPA +93C>T SNP, 10 l of the
PCR products (222 bp) are subjected to digestion with TaiI restriction
enzyme (Fermentas International Inc., Burlington, Canada) while the eval-
uation of LPA+121G>A transition requires an enzymatic digestion with
SduI (Fermentas International Inc., Burlington, Canada). Both the reac-
tions are carried out at 37 °C for 16 h and the digestion fragments are sep-
arated on 3.5% agarose gel (Fig. 3).
Automated sequencing
The DNA sequencing has been performed by using the BigDye chem-
istry (Applied Biosystem, Warrington, Cheshire, UK).
Results and Discussion
To date LPA +93C>T and +121G>A polymorphisms
have been detected through PCR-RFLP assay. Here we
have developed an analysis protocol for the detection of
LPA polymorphisms through Nanogen Technology with
the Universal Reporting System. We have designed dis-
criminator oligonucleotides, necessary for the hybridization
reaction, and we applied speciWc discrimination tempera-
tures to analyze the two SNPs. Afterwards, we have com-
pared results from this technique with those obtained with
a more conventional method. In order to perform this com-
parison we used both the assays to genotype 647 subjects
(Table 2).
The Nanogen analysis evidenced a “call rate” for LPA
+93C>T and LPA +121G>A SNPs of about 88% and
Table 2
Genotype distribution and allele frequency of LPA polymorphisms
SNP Genotype Allele Healthy subjects, N D 647 (%)
LPA +93C>T CC 458 (70.8)
CT 176 (27.2)
TT 13 (2.0)
T 0.16
LPA +121G>A GG 524 (81.0)
GA 120 (18.5)
AA 3 (0.5)
A 0.1087%, respectively. The decreasing in genotyping eYciency
may be due to both PCR failure or sample loss during
puriWcation and insuYcient amount of genomic DNA in
the PCR reaction mix. Samples producing a “no-call”
have been re-ampliWed and retested after puriWcation of
the PCR products in a new experiment. After being per-
formed the new analysis, it has been noted that only 0.02%
of the samples do not produce a result, maybe due to a
low DNA template concentration in the ampliWcation
reaction mixture.
Moreover, we have used the Universal Reporting System
in the DNA microarray analysis, thus reducing the cost of
the original Nanogen procedure. In order to design the
PCR primers for both microarray and PCR-RFLP assays,
genomic DNA sequence (GenBank Accession No.
NT_007422) surrounding the polymorphic sites has been
submitted to BLAST search (Basic Local Alignment
Sequence Tool; http://www.ncbi.nlm.nih.gov/BLAST/). So
it has been possible to evidence regions with high homology
to other genes and to avoid aspeciWc ampliWcations.
BLAST search revealed a great similarity of LPA gene to
the gene encoding for plasminogen (PLG), in particular in
relation to the 5-upstream regions.
Our results evidenced a 100% concordance between
NanoChip analysis and PCR-RFLP assay, so supporting
the use of the Nanogen Technology in the evaluation of
LPA polymorphisms. The samples used as heterozygous
controls in the Nanogen System have been sequenced
(ABI310 automated sequencer) (Fig. 4), so contributing to
produce more accurate results, and to minimize the risk of
sample error.
The sequencing results evidenced the speciWcity of the
ampliWcation products; the primers used in the PCR reac-
tion, annealing to regions showing a lower sequence homol-
ogy to PLG gene (Fig. 4), and the high stringency PCR
cycling conditions prevent the obtainment of aspeciWc
products.
Moreover, the accuracy of our results has been further
conWrmed by the comparison between the electronic micro-
chip analysis and the restriction enzyme digestion, and a
complete agreement has been observed.Fig. 3. LPA +93C>T and +121G>A gel electrophoresis on 3.5% agarose gel. M D DNA ladder (19–1114bp): 19bp, 26bp, 34bp, 37bp, 67bp, 110bp, 124bp,
147bp, 190bp, 242bp, 320bp, 404bp, 489bp, 501bp, 692bp, 900bp, 1114bp.
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required for the detection of each polymorphism; the
hands-on time necessary for the analysis of the two SNPs at
the LPA locus in 96 samples has been reduced of about 4 h
with the electronic microchip strategy, in comparison to
PCR-RFLP assay (Table 3). Another possible advantage of
Nanogen technology is the reduction of the costs per assay:
it has been observed a lowering of the total running cost per
SNP of about 38% (Table 3). Therefore, Nanogen Technol-
ogy allows to analyze a large number of subjects and in par-
ticular to get information regarding polymorphisms at the
LPA locus observed to be involved in the modulation of
Lp(a) levels. This study provides evidence of two possible
aspects, a methodological and a clinical one. The methodo-
logical advantage is due to the rapid LPA +93C>T and
+121G>A SNPs genotyping, and the clinical relevance lies
in the possible characterization of subjects with high Lp(a)
levels, which are known to modulate the vascular disease.
Nevertheless, a limit of our study is to have not taken
into account the comparison between Nanogen Technol-ogy and “Real-time SNPs detection systems”, such as Taq-
Man Probe method, which permits the direct genotyping of
PCR reactions and is the preferred method in many labora-
tories.
In conclusion, our experiments evidence that the elec-
tronic microchips (Nanogen Technology) may represent a
useful tool in the analysis of LPA +93C>T and +121G>A
polymorphisms as a high-throughput system in the SNPs
detection. It permits a high-speed genotyping and it
reduces not only the technician time and the cost for the
SNPs detection, but also the use of hazardous reagents
(ethidium bromide), in comparison to conventional
methods.
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